ADVFN - Advanced Financial Network.
HOME» NYSE » G » GSK Stock Price » GSK Stock News

Glaxosmithkline Share News

 Glaxosmithkline Stock Price
GSK Stock Price
 Glaxosmithkline Stock Chart
GSK Stock Chart
 Glaxosmithkline Stock News
GSK Stock News
 Glaxosmithkline Company Information
GSK Company Information
 Glaxosmithkline Stock Trades
GSK Stock Trades

AstraZeneca Needs To Replenish Drug Pipeline - Chairman

By Marta Falconi ZURICH--AstraZeneca PLC (AZN) aims to replenish its thin pipeline of new drugs through external collaborations and by buying drugs in late stages of development from other drugmakers, Chairman Leif Johansson said in an interview Tuesday. His comments come after the company announced it appointed former Roche head of pharma, Pascal Soriot, as chief executive, to succeed David Brennan, who earlier this year retired abruptly amid shareholder dissatisfaction with the company's performance. "There's a number of medicines going off patent," Mr. Johansson said. "We need to replenish them." The U.K.'s No. 2 drug maker by sales, after GlaxoSmithKline PLC (GSK), has suffered a number of expensive drug-development failures, and shown a poor track record in bringing new medicines to market, analysts say. Some of AstraZeneca's biggest drugs are facing, or will soon face, competition from low-cost generics. Mr. Johansson also said that while the pharmaceutical sector is facing challenges, there are also opportunities, such as the possibility of buying buy late-stage drugs, emerging markets and advances in science, including genome technology, which he touted as a way to learn how the human body works and possibly help find new drugs. Write to Marta Falconi at marta.falconi@dowjones.com Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stock News for Glaxosmithkline (GSK)
DateTimeHeadline
12/18/201407:52:20Glaxo: Study of Shingles Vaccine Meets Primary Objective
12/11/201407:47:33GlaxoSmithKline Seeks Variation on Authorization for Ambrisentan
12/04/201412:13:18GlaxoSmithKline Decides Against Established Products Sale After...
12/03/201423:43:31Array BioPharma to Regain Global Rights to Cancer Therapy
12/03/201423:42:41Array BioPharma to Regain Global Rights to Cancer Therapy From...
11/26/201420:30:42Ebola Vaccine Appears Safe in Early Test -- Update
11/26/201419:40:13Ebola Vaccine Seems Safe, Researchers Say
11/26/201419:15:45Ebola Vaccine Seems Safe, Triggers Immune Response in Early Test
11/26/201418:31:46Novartis to Divest Nicotine Patch Habitrol to Comply with FTC
11/12/201417:05:57GlaxoSmithKline Seeks Variation of Authorization for Anemia Treatment
11/06/201412:17:28LONDON MARKETS: FTSE Ends Higher After ECB Hints At Stimulus
11/05/201407:07:50GlaxoSmithKline Files Regulatory Submissions in U.S., Europe...
10/24/201414:11:02Flu-Shot Supply Dented by Production Woes
10/23/201412:38:04LONDON MARKETS: FTSE Rides European Optimism, But Tesco Slumps
10/23/201403:55:21LONDON MARKETS: Tesco Slumps, Sends FTSE Lower For First Time...
10/22/201410:04:35LONDON MARKETS: Glaxo Gives FTSE 100 A Shot In The Arm
10/22/201409:55:11LONDON MARKETS: GSK Lifts FTSE 100 On Earnings, Ebola Vaccine
10/22/201409:51:50U.S. Hot Stocks: Hot Stocks to Watch
10/22/201407:51:29Genmab 3Q Sales of Leukemia Drug Arzerra At GBP13.8 Million
10/20/201409:05:46GlaxoSmithKline plc 3Q 2014 -- Forecast

Glaxosmithkline and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad